Literature DB >> 27376434

A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment.

Malik Asif Humayun1, Ruth Poole2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27376434     DOI: 10.14310/horm.2002.1656

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


× No keyword cloud information.
  13 in total

Review 1.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 2.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

4.  New-onset insulin-dependent diabetes due to nivolumab.

Authors:  Ali A Zaied; Halis K Akturk; Richard W Joseph; Augustine S Lee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-03-28

5.  Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.

Authors:  Giulia Lanzolla; Alberto Coppelli; Mirco Cosottini; Stefano Del Prato; Claudio Marcocci; Isabella Lupi
Journal:  J Endocr Soc       Date:  2019-01-08

6.  Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

Authors:  Jeroen M K de Filette; Joeri J Pen; Lore Decoster; Thomas Vissers; Bert Bravenboer; Bart J Van der Auwera; Frans K Gorus; Bart O Roep; Sandrine Aspeslagh; Bart Neyns; Brigitte Velkeniers; Aan V Kharagjitsingh
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

7.  Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.

Authors:  Ya Liu; Hao Zhang; Li Zhou; Weichun Li; Le Yang; Wen Li; Kezhou Li; Xubao Liu
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 8.  Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.

Authors:  Xiaofei Huang; Mei Yang; Liu Wang; Libo Li; Xiaowei Zhong
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 9.  Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports.

Authors:  Anmol Cheema; Bhaktidevi Makadia; Tejas Karwadia; Ravneet Bajwa; Mohammad Hossain
Journal:  World J Oncol       Date:  2018-03-08

10.  Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.

Authors:  Taha Alrifai; Faisal Shaukat Ali; Sameer Saleem; Diana Carolina Miranda Ruiz; Dana Rifai; Sundas Younas; Faisal Qureshi
Journal:  Case Rep Oncol Med       Date:  2019-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.